Phio Pharma Q2 net loss $1.8M, cash $4.7M; PH-762 trial progresses

Phio Pharmaceuticals Corp.

2024-Q2 EPS reported -$7.85

Cash at June 30, 2024: $4.7M vs $8.5M at Dec 31, 2023; net loss $1.8M vs $2.5M year ago.
Phase 1b trial for PH-762 received positive SMC safety recommendation; dose escalation and next cohort enrollment ongoing.
Nasdaq compliance regained for minimum $1.00 bid price after 9:1 reverse stock split effective July 5, 2024.
Appointed Robert M. Infarinato as VP and CFO effective August 1, 2024.
Entered exploratory collaboration with global skin care company for INTASYL cosmeceutical compounds.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.